ImmuCell Co. (NASDAQ:ICCC) Short Interest Up 490.0% in November

ImmuCell Co. (NASDAQ:ICCC) was the recipient of a significant growth in short interest in November. As of November 15th, there was short interest totalling 23,600 shares, a growth of 490.0% from the October 31st total of 4,000 shares. Approximately 0.4% of the company’s stock are sold short. Based on an average daily volume of 34,600 shares, the short-interest ratio is currently 0.7 days.

ImmuCell Stock Up 10.8 %

NASDAQ:ICCC traded up $0.40 during trading hours on Friday, reaching $4.12. The company’s stock had a trading volume of 17,047 shares, compared to its average volume of 18,967. The company has a market cap of $36.71 million, a price-to-earnings ratio of -8.40 and a beta of 0.56. ImmuCell has a one year low of $3.34 and a one year high of $5.59. The business’s 50-day moving average is $3.62 and its 200-day moving average is $3.97. The company has a debt-to-equity ratio of 0.36, a current ratio of 3.11 and a quick ratio of 1.44.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.